Muscle Hypertonia Treatment Market Research 2022-30 - Reports and Insights

: August 2019

Improving Treatment Seeking Rate would drive the Muscle Hypertonia Treatment Market


Reports and Insights (R&I) has published a new report titled, Muscle Hypertonia Treatment Market: Opportunity Analysis and Future Assessment 2020 to 2028

Global Muscle Hypertonia Treatment Market, by Drug Type (Baclofen, Diazepam, Dantrolene), By Prognosis (Mild Condition, Moderate Condition, Severe Condition) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.

As per the report, the growing incidence of muscle hypertonia and improving treatment-seeking rates are the factors attributed to growth in the global muscle hypertonia treatment market. Hypertonia is used synonymously with muscle spasticity and muscle rigidity.

Muscle hypertonia is a common finding in patients with upper motor neuron syndrome. Muscle hypertonia is characterized by increased muscle tone which causes stiffness in the hands and legs. Causes of muscle hypertonia can be blown to the head, stroke, brain tumors, neurodegenerative diseases, cerebral palsy, multiple sclerosis, Parkinson’s disease, etc. Muscle hypertonia limits the movement of joints hence limits the body functions such as walking, balancing, etc. If hypertonia is severe, it can cause a joint to become frozen, which is called a joint contracture.

The prognosis of muscle hypertonia depends on the severity of the disease and the underlying cause. For instance, in the case of cerebral palsy muscle hypertonia can last lifelong. In other conditions, hypertonia may worsen along with the underlying disease. If hypertonia is mild it has little or no effect on a person’s health. Moderate hypertonia may affect joint contracture. Severe muscle hypertonia causes immobility, risk of bone fracture, infection, bedsores, pneumonia, etc. 

Furthermore, Reports and Insights (R&I) Study identifies that increasing awareness about muscle hypertonia is leading to increasing treatment-seeking rates in countries such as the U.S. Treatment of muscle hypertonia includes physical therapy and pharmacological therapy. The aim of physical therapy is to inhibit excessive muscle tone. Physiotherapy can control muscle hypertonia through the use of stretching. Local anesthetics can decrease reflective activity. Shock wave therapy is being used to treat muscle hypertonia since 1997.

Pharmacological therapy involves treatment with muscle relaxing drugs such as baclofen, diazepam, and dantrolene. Baclofen is generally the drug of choice for spinal cord types of spasticity, while sodium dantrolene is the only agent that acts directly on muscle tissue. All of these drugs can be taken by mouth, but baclofen may also be injected directly into the cerebrospinal fluid through an implanted pump. Botulinum toxin is often used to relieve hypertonia in a specific area of the body.

R&I Study identifies some of the key participating players in the Muscle Hypertonia Treatment market globally are Apotex Corporation, Sanis Health Inc., Sterimax Inc., Piramal Critical Care Inc., Mallinckrodt Inc., Novartis AG, Valeant Pharmaceuticals, Pfizer Inc., Procter & Gamble Pharmaceuticals, Par Pharmaceutical, Cardinal Health, etc.

About Reports and Insights:

Reports and Insights (R&I) is committed to provide deep insights that serve as creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.

Contact Us

Reports and Insights

Tel: +1-(718)-312-8686

For Sales Query[email protected]

For New Topics & Other Info: [email protected]